NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated July 13, 2026

Empagliflozin

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for type 2 diabetes and to reduce cardiovascular death in patients with established cardiovascular disease. It also has FDA approval for heart failure with reduced ejection fraction. The EMPA-REG OUTCOME trial demonstrated significant cardiovascular mortality benefit.

Evidence tier
Strong
Indexed sources
9 2024–2026
Interactions
0
Category
Prescription
Read the sources → Compare profiles
Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for type 2 diabetes and to reduce cardiovascular death in patients with established cardiovascular disease. NutriStack rates the supporting evidence as strong. Common adult dosing is 10–25 mg once daily in the morning (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 9 sources.

What it's good for
  • Lowers HbA1c by 0.5–0.8%
  • Significant cardiovascular mortality reduction (38% in EMPA-REG OUTCOME)6,5
  • Heart failure hospitalization reduction3,4
  • Weight loss (2–3 kg)
  • Blood pressure reduction (3–5 mmHg systolic)
What to watch for
  • Genital mycotic infections (yeast infections)
  • Urinary tract infections
  • Increased urination (polyuria)
  • Severe renal impairment (eGFR <20 mL/min for diabetes indication)7
  • Dialysis

The bottom line

Evidence rating strong. Most-documented uses: lowers hba1c by 0.5–0.8%, significant cardiovascular mortality reduction (38% in empa-reg outcome), heart failure hospitalization reduction. 9 sources indexed (2024–2026), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Selectively and reversibly inhibits the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, which is responsible for approximately 90% of renal glucose reabsorption. This reduces the renal glucose threshold and causes glycosuria (urinary glucose excretion of 60–80 g/day), lowering plasma glucose independent of insulin. Secondary effects include osmotic diuresis, natriuresis, blood pressure reduction, and weight loss.

Class
SGLT2 Inhibitor
Dosing

Dosing & protocol.

Common range
10–25 mg once daily in the morning (as prescribed by your physician)
Recommended form
Oral tablet

Can be taken with or without food. Best taken in the morning to minimize nocturia.

Safety

Full safety detail.

Side effects

  • Genital mycotic infections (yeast infections)
  • Urinary tract infections
  • Increased urination (polyuria)
  • Volume depletion and hypotension
  • Diabetic ketoacidosis (rare, may present with near-normal glucose)
  • Fournier gangrene (necrotizing fasciitis of perineum, very rare)
  • Hypoglycemia when combined with insulin or sulfonylureas

Contraindications

  • Severe renal impairment (eGFR <20 mL/min for diabetes indication)7
  • Dialysis
  • Known hypersensitivity to empagliflozin1,2
  • History of diabetic ketoacidosis
  • Type 1 diabetes6
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Meta-analyses & systematic reviews

5

Reference material

4
FAQ

Common questions.

Quick answers about Empagliflozin, drawn from the data on this page.

What is Empagliflozin?

Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for type 2 diabetes and to reduce cardiovascular death in patients with established cardiovascular disease. It also has FDA approval for heart failure with reduced ejection fraction. The EMPA-REG OUTCOME trial demonstrated significant cardiovascular mortality benefit.

What is Empagliflozin used for?

Commonly cited benefits of Empagliflozin include: Lowers HbA1c by 0.5–0.8%; Significant cardiovascular mortality reduction (38% in EMPA-REG OUTCOME); Heart failure hospitalization reduction; Weight loss (2–3 kg); Blood pressure reduction (3–5 mmHg systolic). NutriStack rates the overall evidence as strong.

What is a typical dose of Empagliflozin?

A typical adult dose of Empagliflozin is 10–25 mg once daily in the morning (as prescribed by your physician). The commonly recommended form is Oral tablet. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Empagliflozin?

Reported side effects include genital mycotic infections (yeast infections), urinary tract infections, increased urination (polyuria), volume depletion and hypotension, diabetic ketoacidosis (rare, may present with near-normal glucose), fournier gangrene (necrotizing fasciitis of perineum, very rare). This is educational information; check with a healthcare professional before use.

How strong is the evidence for Empagliflozin?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Empagliflozin in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

Download on the App Store → Read the methodology

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.